Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials
Open Access
- 1 November 2020
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 22 (11), 2160-2171
- https://doi.org/10.1002/ejhf.2015
Abstract
Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials. Methods and results Adults with established HFrEF, New York Heart Association (NYHA) functional class >= II, ejection fraction <= 35%, elevated natriuretic peptides and either current hospitalization for heart failure or history of hospitalization/emergency department visit for heart failure within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic-guided dosing: 25, 37.5, or 50 mg bid). A total of 8256 patients [male (79%), non-white (22%), mean age 65 years] were enrolled with a mean ejection fraction 27%, ischaemic aetiology in 54%, NYHA class II 53% and III/IV 47%, and median N-terminal pro-B-type natriuretic peptide 1971 pg/mL. Heart failure therapies at baseline were among the most effectively employed in contemporary heart failure trials. GALACTIC-HF randomized patients representative of recent heart failure registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure <100 mmHg (n = 1127), estimated glomerular filtration rate <30 mL/min/1.73 m(2) (n = 528), and treated with sacubitril/valsartan at baseline (n = 1594). Conclusions GALACTIC-HF enrolled a well-treated, high-risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation.This publication has 31 references indexed in Scilit:
- Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registryEuropean Heart Journal, 2016
- Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart FailureJournal of the American College of Cardiology, 2016
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureThe New England Journal of Medicine, 2014
- Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart FailureJAMA, 2013
- Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man studyThe Lancet, 2011
- The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trialThe Lancet, 2011
- Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart FailureScience, 2011
- Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction: A Meta-Analytic ApproachJournal of the American College of Cardiology, 2010
- Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart FailureThe EVEREST Clinical Status TrialsJAMA, 2007
- Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart FailureThe EVEREST Outcome TrialJAMA, 2007